Cargando…
Efficacy of tripterygium glycosides for diabetic nephropathy: a meta-analysis of randomized controlled trials
BACKGROUNDS: Diabetic nephropathy (DN) is one of the most important clinical complications of diabetes mellitus (DM) and is the most common cause of end-stage renal disease. Currently, there is no highly effective medicine that can prevent, halt, or reverse the progressive course of DN. Initial clin...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8425142/ https://www.ncbi.nlm.nih.gov/pubmed/34493223 http://dx.doi.org/10.1186/s12882-021-02487-8 |
_version_ | 1783749798865666048 |
---|---|
author | Guo, Hua-Bin Peng, Jia-Qing Xuan Wang Zhang, Ke-Kai Zhong, Guang-Zhi Chen, Wei-Hong Shi, Gui-Xin |
author_facet | Guo, Hua-Bin Peng, Jia-Qing Xuan Wang Zhang, Ke-Kai Zhong, Guang-Zhi Chen, Wei-Hong Shi, Gui-Xin |
author_sort | Guo, Hua-Bin |
collection | PubMed |
description | BACKGROUNDS: Diabetic nephropathy (DN) is one of the most important clinical complications of diabetes mellitus (DM) and is the most common cause of end-stage renal disease. Currently, there is no highly effective medicine that can prevent, halt, or reverse the progressive course of DN. Initial clinical data showed that Tripterygium glycosides (TGs), a traditional Chinese medicine, can decrease proteinuria in patients with DN. OBJECTIVES: The objective of the present study is to investigate the efficacy and safety of TGs for the treatment of DN through meta-analysis of randomized controlled trials (RCTs). METHODS: All RCTs of TGs for DN were collected from The China National Knowledge Infrastructure (CNKI), PubMed, Web of Science, Wanfang Data, Chinese Biomedical Literature Database (CBM), China Science and Technology Journal Database (VIP) by setting the study inclusion and elimination standards. Two reviewers evaluated the quality of the trials and extracted the data independently. RevMan 5.4 software was used for meta-analyses. The primary outcome was a change in 24-hours urinary total protein (24 h TUP). RESULTS: 26 RCTs with 1824 participants were identified. Studies were assessed using the Cochrane risk of bias tool. The overall effects showed that TGs was compared with the controls, TGs showed significant effects in reducing 24 h TUP [WMD = -0.84, 95 % CI (-1.09, -0.59)], elevating serum albumin [WMD = 2.88, 95 % CI (1.87, 3.90)], and the total efficiency [OR = 4.08, 95 % CI (2.37, 7.04)]. This effect was consistent across the subgroups of period of intervention. CONCLUSIONS: The present research showed that TGs was significantly associated with improvement of renal function in patients with DN. TGs offers a novel approach to the treatment of DN, more high-quality RCTs are needed for a better understanding of the role of TGs in DN therapy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12882-021-02487-8. |
format | Online Article Text |
id | pubmed-8425142 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-84251422021-09-10 Efficacy of tripterygium glycosides for diabetic nephropathy: a meta-analysis of randomized controlled trials Guo, Hua-Bin Peng, Jia-Qing Xuan Wang Zhang, Ke-Kai Zhong, Guang-Zhi Chen, Wei-Hong Shi, Gui-Xin BMC Nephrol Research Article BACKGROUNDS: Diabetic nephropathy (DN) is one of the most important clinical complications of diabetes mellitus (DM) and is the most common cause of end-stage renal disease. Currently, there is no highly effective medicine that can prevent, halt, or reverse the progressive course of DN. Initial clinical data showed that Tripterygium glycosides (TGs), a traditional Chinese medicine, can decrease proteinuria in patients with DN. OBJECTIVES: The objective of the present study is to investigate the efficacy and safety of TGs for the treatment of DN through meta-analysis of randomized controlled trials (RCTs). METHODS: All RCTs of TGs for DN were collected from The China National Knowledge Infrastructure (CNKI), PubMed, Web of Science, Wanfang Data, Chinese Biomedical Literature Database (CBM), China Science and Technology Journal Database (VIP) by setting the study inclusion and elimination standards. Two reviewers evaluated the quality of the trials and extracted the data independently. RevMan 5.4 software was used for meta-analyses. The primary outcome was a change in 24-hours urinary total protein (24 h TUP). RESULTS: 26 RCTs with 1824 participants were identified. Studies were assessed using the Cochrane risk of bias tool. The overall effects showed that TGs was compared with the controls, TGs showed significant effects in reducing 24 h TUP [WMD = -0.84, 95 % CI (-1.09, -0.59)], elevating serum albumin [WMD = 2.88, 95 % CI (1.87, 3.90)], and the total efficiency [OR = 4.08, 95 % CI (2.37, 7.04)]. This effect was consistent across the subgroups of period of intervention. CONCLUSIONS: The present research showed that TGs was significantly associated with improvement of renal function in patients with DN. TGs offers a novel approach to the treatment of DN, more high-quality RCTs are needed for a better understanding of the role of TGs in DN therapy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12882-021-02487-8. BioMed Central 2021-09-07 /pmc/articles/PMC8425142/ /pubmed/34493223 http://dx.doi.org/10.1186/s12882-021-02487-8 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Guo, Hua-Bin Peng, Jia-Qing Xuan Wang Zhang, Ke-Kai Zhong, Guang-Zhi Chen, Wei-Hong Shi, Gui-Xin Efficacy of tripterygium glycosides for diabetic nephropathy: a meta-analysis of randomized controlled trials |
title | Efficacy of tripterygium glycosides for diabetic nephropathy: a meta-analysis of randomized controlled trials |
title_full | Efficacy of tripterygium glycosides for diabetic nephropathy: a meta-analysis of randomized controlled trials |
title_fullStr | Efficacy of tripterygium glycosides for diabetic nephropathy: a meta-analysis of randomized controlled trials |
title_full_unstemmed | Efficacy of tripterygium glycosides for diabetic nephropathy: a meta-analysis of randomized controlled trials |
title_short | Efficacy of tripterygium glycosides for diabetic nephropathy: a meta-analysis of randomized controlled trials |
title_sort | efficacy of tripterygium glycosides for diabetic nephropathy: a meta-analysis of randomized controlled trials |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8425142/ https://www.ncbi.nlm.nih.gov/pubmed/34493223 http://dx.doi.org/10.1186/s12882-021-02487-8 |
work_keys_str_mv | AT guohuabin efficacyoftripterygiumglycosidesfordiabeticnephropathyametaanalysisofrandomizedcontrolledtrials AT pengjiaqing efficacyoftripterygiumglycosidesfordiabeticnephropathyametaanalysisofrandomizedcontrolledtrials AT xuanwang efficacyoftripterygiumglycosidesfordiabeticnephropathyametaanalysisofrandomizedcontrolledtrials AT zhangkekai efficacyoftripterygiumglycosidesfordiabeticnephropathyametaanalysisofrandomizedcontrolledtrials AT zhongguangzhi efficacyoftripterygiumglycosidesfordiabeticnephropathyametaanalysisofrandomizedcontrolledtrials AT chenweihong efficacyoftripterygiumglycosidesfordiabeticnephropathyametaanalysisofrandomizedcontrolledtrials AT shiguixin efficacyoftripterygiumglycosidesfordiabeticnephropathyametaanalysisofrandomizedcontrolledtrials |